Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close o...
Read moreNorthSea Therapeutics B.V. today announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD), an orphan live...
Read moreProceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-...
Read moreSource BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-st...
Read moreVivet Therapeutics announces the financing of EUR 4.9 million received from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX)...
Read moreCollaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC
Read moreSparingVision today announces a key advancement in its Phase I/II clinical trial for SPVN06, the Company’s lead gene-agnostic investigational gene therapy for the treatment of retinitis pigmentosa (...
Read moreThis pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates
Read moreAs part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-ALD patients with cerebral Adrenoleukodystrophy (cALD)
Read moreMineralys Therapeutics today presented data from the Target-HTN Phase 2 trial that further defines an endotype-specific targeted approach for treating uncontrolled or resistant hypertension with lorun...
Read moreThis capital increase will allow Kynexis to advance the development of KYN5356, an innovative quinurenine aminotransferase II (KAT-II) enzyme inhibitor, for the treatment of cognitive impairment assoc...
Read moreEndotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm
Read more